The 8th Annual World Congress of Vaccine
About WCV - 2016

Following on the successful organizing of WCV-2015, we are pleased to announce the next WCV conference will be held during April 25-27, 2016 in Dalian, China. With the theme of “Creating the Best Shields against Diseases”, we will once again offer professionals in the field of vaccine a multidisciplinary informative platform.
WCV-2016 contributes to provide a unique platform which will bring together thought leaders from pharmaceutical, biotech companies, consultants, regulatory authorities and academics, to present the latest research results, ideas, developments, applications and business prospects in Vaccine Research and Technologies, Vaccine Drugs, and Production, Vaccine Market Trend & Policy, etc.

Renowned Speakers
Dr. Kelly T. McKee, Vice President, Quintiles Inc., USA Dr. Michael Hanna, Founder and Chairman, Vaccinogen, USA
Dr. Priyabrata Pattnaik,Director of Worldwide Vaccine Initiative, Merck Millipore, Singapore Dr. Linong Zhang, Director, Sanofi Pasteur Biologics Co, USA
Dr. Rebecca Martin, Director of the Global Immunization Division (GID), CDC, USA Dr. Pierre Vandepapeliere, CEO, ImCyse, Belgium
Dr. Erik B. Lindblad, Technical Director, CSO, Brenntag Biosector, Denmark Dr. Ines Atmosukarto, Chief Executive Officer, Lipotek Pty Ltd , Australia
Dr. Heather Callender-Potters, Vice-Chairman, PharmaJet, Inc., USA Dr. Francis O. Eko, Professor, Department of Microbiology, Biochemistry and Immunology Morehouse School of Medicine, USA
Dr. Klaus Schwamborn, Vice President, Valneva SE, France Dr. E. Yvonne Lewis, Executive Director, Universal Kidney Foundation, USA
Highlights of the WCV-2016
  • 300+ Attendees Coming from All over the World to Exchange Ideas, Build New Networks, and Foster Friendships
  • 140+ Oral Presentations Covering the Hot Topics and Cutting-edge Technology in the Field of Vaccine
  • 80+ Exhibitors and 30+ Posters Showcasing the Emerging New Products and Technologies
  • Social Activities and Networking, Field Trip and Tech-tour, Build Partnerships, Find Huge Opportunities and Markets for Your Business over the World
  • Opportunities to Visit Beijing Natural and Cultural Landscape
Program Layout
Cluster 1: Main Conference
Part One:
Opening Ceremony and Nobel Laureate Forum
Part Two:
Keynote Forum
Cluster 2: Scientific Program

• Stream 1: Global Immunization Projects and Global Health
• Stream 2: The Hot Topics in Vaccinology
• Stream 3: Novel Vaccine Technology and Approaches
• Stream 4: Human Vaccine for Infectious Diseases
• Stream 5: Human Vaccine for Non-Infectious Diseases
• Stream 6: Veterinary Vaccine
• Stream 7: Vaccine Bioprocessing, Production and Manufacturing

Cluster 3 Business Development

• Industrial Sponsored Symposia
• Matchmaking and Biopartnering
• Round Table Discussion

Cluster 4 Posters and EXPO
WCV-2016 provides an ideal platform to showcase your novel technologies and products in China. It is developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent repeated opportunities for delegates to visit the exhibits.


Why Reserve a Booth at WCV-2016
  • To Meet Face-to-Face with the International Movers and Shakers in the Field of vaccines
  • To Meet with Key Decision Marker around the World
  • To Explore Business Opportunities in China and beyond
  • To Spotlight Advanced Technologies and Their Scientific and Commercial Applications
  • To Take Advantage of the Conference's Captive Audience and Networking Opportunities within
Cluster 5: Sponsorship
WCV-2016 is one of the most effective international marketing platforms in the field of Vaccine and related biotechnology, which offers a wide range of sponsoring categories for branding and highlighting your company in order to achieve the best publicity.
  • Expand Your Business - A Cost Effective Sponsorship
  • Get Cost and Time Effective Marketing Exposure and Boost Your Brand Recognition
  • Set Up Stronger Alliances, New Partnerships
  • Showcase Products and Services to a Targeted Prospects of Decision-makers
  • Opportunity to Speak and Announce Recent Company Development
  • Network from 800+ Professionals Offering Opportunities, before, during and after the Conference
Cluster 6: Social Events
• Culture Activities-Art Performance and Show
• Cocktail Social Networking
• City Tour As Requested
• Field Trip to Universities/Industries, and Networking Tour
                
Media
China Local Time
Days to Go!
News Release

Early bird registration for speech opportunity is open.
The scientific program is releasing soon.
♦ Call for speakers, exhibitors and sponsors worldwide.
♦ Call for media partners and advertiser worldwide.
Register now to enjoy favorable discount.

Hosting Organization

Information Research Center of International Talent, China State Administration of Foreign Experts Affairs, China

Operating Organization

Zhen-Ao Group

SHUANGDI, INC.

BIT Group Global Ltd.

Official Travel Agency
Past Renowned Speakers
Dr. Istvan Toth,
Professor,
University of Queensland,
Australia
Dr. Duncan D. Adams,
Director,
University of Otago,
New Zealand
Dr. Trent Carrier,
Chief Business Officer,
Biologics Consulting Group Inc,
USA
Dr. Andrew Potter,
CSO
Pan-Provincial,
Canada
Dr. Michael Vajdy,
Co-Founder & Chief Scientific Officer,
EpitoGenesis, Inc,
USA
Dr. Giulio Tarro,
Professor,
D. Cotugno Hospital,
Italy
Dr. Anton Dormer,
President,
Dormer-Owusu BioInstitute, Inc.,
USA
Dr. Stanley Chang,
Chief Executive Officer,
Medigen Biotechnology Corp,
Taiwan
Dr. Nikolai Petrovsky,
Director
Vaxine Pty Ltd,
Australia
Dr. Roman Prymula,
Chairman,
Czech Immunisation Society,
The Czech Republic
Dr. Ralf Ostendorp,
Vice President,
Protein Sciences, MorphoSys AG,
Germany
Dr. Grant Shimamoto,
Senior Scientist,
Amgen,
USA
Dr. Myron Arlen,
CEO and President,
Neogenix Oncology Inc.,
USA
Dr. Michael A. Swit,
Vice President,
The Weinberg Group Inc.,
USA
Dr. Zhi Liu,
Professor,
University of North Carolina,
USA
Dr. Giulio F. Tarro,
Adjunct Professor,
Temple University,
Italy
Dr. Jishu Shi,
Professor,
Kansas State University,
USA
Dr. Frederic J. Deschamps,
Professor,
Department of Occupational Health,
France
Dr. Hossein A Ghanbari,
CEO,
Panacea Pharmaceuticals, Inc,
USA
Dr. Michel Klein,
Biochemistry Professor and CEO IRICoR,
Institute for Research In Immunology and Cancer,
Université de Montréal,
Canada
Dr. Richard L Amoroso,
Director,
Noetic Advanced Studies Institute,
Physics Lab,
USA
Dr. Young Chul Sung,
Professor,
Pohang University of Science and Technology,
CEO and Chairman,
Genexine co.,
Korea
Dr. Martin Scholz,
CSO,
LEUKOCARE AG,
Germany
Dr. Steffen Nock, 
VP & Global Head of Biologic,
Teva Pharmaceuticals,
Germany
Dr. George Chryssomalis, 
Vice President,
R&D Strategy, Global Research & Development, Acting Head R&D China ,
Sanofi Pasteur,
France
Dr. Hongzhou Lu, 
Director,
Shanghai Public Health Clinical Center,
China
Dr. Yoshinori Hayakawa,
Professor,
Toin University of Yokohama,
Japan
Dr. Dionisio Jose Herrera Guibert, 
Director,
Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET),
USA
Dr. Lilin Ye, 
Professor,
Third Miliatary Medical University,
USA
Dr. Luis Martin, 
Chief Science Officer,
PREVENT,
Canada
Dr. Qing Zhu, 
Professor,
Institute of Materia Medica, CAMS/PUMC,
China
Dr. Xin Dong Guo, 
Professor,
Beijing University of Chemical Technology,
China
Dr. Suraiya Rasheed,
Professor & Director,
Keck School of Medicine, University of Southern California,
USA
Dr. Alicja E. Grzegorzewska, 
Professor,
Poznan University of Medical Sciences,
Poland
Dr. Fu Shi Quan, 
Professor,
Kyung Hee University,
Seoul Korea
Dr. Juan Carlos Vazquez Chagoyan, 
Professor,
Universidad Autanoma del Estado de Mexico,
Mexico
Dr. Yung Chang, 
Professor,
Arizona State University,
USA
Dr. Lutsch Charles, 
Chief Scientific Officer,
Shantha Biotechnics Ltd ( A Sanofi Company),
France
Dr. Priyabrata Pattnaik, 
Director
Asia Vaccine Initiative, Merck Millipore,
Singapore
Dr. Michael Li, 
Vice President of R&D,
RJ Bio Process (Suzhou) Company Limited,
China
Dr. Francois Bertrand, 
Asia Pacific Technical Development & Marketing Manager,
SEPPIC,
China
Dr. Aizhen Guo, 
Professor,
College of Veterinary Medicine, Huazhong Agricultural University,
China
Dr. Shyan-Song Chiou, 
Professor,
National Chung Hsing University,
Taiwan
Dr. T.-C. Wu, 
Professor,
The Johns Hopkins Medical Institutions,
USA
Dr. Vincent G. Brichard 
Senior VP & Head 
GlaxoSmithKline Biologicals
Belgium
Dr. Shou-Bai Chao
Senior VP
Manufacturing,
MedImmune LLC
USA
Dr Alain Bouckenooghe,
Regional Head Asia Pacific,
Sanofi Pasteur,
Singapore
Dr. Theodore F. Tsai
Senior VP
Novartis Vaccines
USA
Dr. W. Ripley Ballou
Vice President
GlaxoSmithKline Biologicals
Belgium
Dr. Rainer Henning 
Chief Executive Officer 
Biomay AG
USA
Dr. Florian Schodel 
Global Head 
Philimmune LLC
USA
Dr. Daniel H. Zimmerman 
Senior VP & Head
CEL-SCI Corporation
USA
Dr. Charles MY Lim
CEO
Asia Pacific & China
BIA Separations Co. Ltd.
Austria
Dr. Scott M. Wheelwrigh 
VP&COO
Innovent Biologics Inc
USA
Dr. Li Shi
CEO
Zerun Biotechnology
China
Dr. Erich Hugo Cerny 
CSO
Chilka Limited
Switzerland
Dr. Mariano Young Jr. 
Director
Pfizer Inc 
China
Dr. Jean-Denis SHU
Medical Director
Sanofi Pasteur
China
Dr. Malcolm E Thomas 
President & CEO
Arbovax, Inc.
USA
Dr. Dexiang Chen 
Senior Technical Officer
PATH
USA
Dr. Amy J Weiner
Senior Program Officer
Bill  Melinda Gates Foundation
USA
Dr. Shohreh Issazadeh-Navikas 
Professor
University of Copenhagen
Denmark
Dr. Linong Zhang 
Deputy Director
Sanofi Pasteur Biologics Co.
USA
Dr. Klaus Hermansen 
Senior Vaccine & Process
Specialist
NNE Pharmaplan
Denmark
Dr. Pramod Srivastava
Professor
University of Connecticut Health Center
USA
Dr. Mei X. Wu 
Associate Professor
Harvard Medical School
USA
Dr. Yao Zhi Q 
Director
HCV/HIV Program
East Tennessee State University
USA
Dr. Hua-Ji Qiu 
Professor
Chinese Academy of Agricultural Sciences
China
Dr. Lili Sui
Fast Trak China Leader
GE Healthcare, Lifesciences
China
Dr. Timm C. Harder
Professor
O.I.E., FAO & National Reference Laboratory
Germany
Dr. Zhen F. Fu
Professor
University of Georgia
USA
Dr. Jianzhu Chen
Professor
The David H. Koch Institute for Integrative Cancer Research
USA
Dr. Yuanan Lu
Professor
University of Hawaii
USA
Dr. Kejian Yang 
Vice President, Virology and Vaccine
Biomedical Research Models, Inc.
USA
Dr. Wenzhi Xue
Sr. Group Leader,
Biological R&D, Merck Animal Health
USA
Dr. Tyler Martin
President & Chief Medical Officer
Dynavax Technologies
USA
Dr. Rudolf Valenta
Professor
Medical University of Vienna
Austria
Dr. Roa Gudding
Director
National Veterinary Institute
Norway
Dr. Pierre-Marie Borne,
Public Affairs Director, DVM, 
Public Health Zoonoses & Food Safety,
France
Dr. Nathalie Garcon,
Vice President,
GlaxoSmithKline Biologicals,
Belgium
Dr. Leonard P. Ruiz,
President,
International Medica Foundation,
USA
Dr. A.M. Palache,
Director,
Abbott Biologicals,
The Netherlands
Dr. Le Sun,
President & CEO,
AbMax Biotechnology Co.,
China
Dr. Richard Walker, 
Director,
PATH,
USA
Dr. Kelly McKee, 
Vice President,
Quintiles Transnational Corporation,
USA
Dr. Richard L. Amoroso, 
Professor,
Noetic Advanced Studies Institute,
USA
Dr. Andrew A. Potter, 
CEO,
VIDO / InterVac,
Canada
Dr. Charles M. Y. Lim,
CEO
Asia Pacific & China, BIA Separations,
Austria
Dr. Dieter Klein,
Professor,
University of Veterinary Medicine,
Austria
Dr. Edgar M Carvalho, 
Professor,
Federal University of Bahia,
Brazil
Dr. Guang Zeng, 
Professor,
Chinese Center for Disease Control and Prevention,
China
Dr. Han Sang Yoo, 
Professor,
Seoul National University,
South Korea
Dr. Harry L.T. Mobley, 
Professor,
University of Michigan Medical School,
USA
Dr. Jude E Uzonna, 
Associate Professor,
University of Manitoba,
Canada
Dr. Niels Guldager,
Senior Technology Partner,
NNE Pharmaplan,
Denmark
Dr. Riccardo Cortese, 
CEO,
Okairos,
Italy
Dr. Ruobing Wang,
Associate Professor,
University of Washington,
USA
Dr. Ronald L. Thune, 
Professor,
Louisiana State University,
USA
Dr. Takashi Kei Kishimoto,
Chief Scientific Officer,
Selecta Biosciences,
USA
Dr. Ted M. Ross,
Associate Professor,
University of Pittsburgh,
USA
Dr. Vladimir Motin, 
Associate Professor,
University of Texas Medical Branch,
USA
Dr. Michel De Wilde,
Senior Vice President,
Sanofipasteur,
Belgium
Dr. John W. Shiver,
Vice President & Worldwide Basic Research Franchise Head,
Vaccines. Merck & Co., Inc.,
USA
Dr. Rahul Singhvi,
CEO & President,
Novavax Inc.,
USA
Dr. John E. Tedstrom,
President & CEO,
Global Business Coalition on HIV/AIDS, Tuberculosis & Malaria (GBC),
USA
Dr. Wen Yumei,
Academician,
Chinese Academy of Engineering,
China
Dr. Nathalie Garcon,
Vice President ,
GSK Biologicals,
USA
Dr. Peter H. Khoury,
Vice President,
Global Marketing Baxter BioScience, Vaccines,
USA
Dr. Oliver Kisker,
Senior Vice President,
Merck KGaA,
Germany
Dr. Jaap Goudsmit,
Chief Scientific Officer,
Crucell,
The Netherlands
Dr. B. G. Rhee,
Executive Vice President,
Green Cross Corporate,
Korea
Dr. Jerald C. Sadoff,
Chief Medical Officer,
Crucell,
The Netherlands
 Dr. Eluemuno. R. Blyden,
CEO,
AfriVax Inc,
USA
Dr. Francis E. André,
Ex-Vice President,
GlaxoSmithKline Biologicals,
Belgium
Dr. Frank J. Malinoski,
Chief Medical Officer,
Liquidia Technologies,
USA
Dr. Malcolm Thomas,
President and CEO,
Arbovax, Inc.,
USA
Dr. Mark R Alderson,
Director,
Pneumococcal Vaccine Project,
PATH,
USA
Dr. Thomas Muster,
CEO,
AVIR Green Hills Biotechnology,
Austria
Dr. Robert Lambkin-Williams,
CEO,
Retroscreen Virology Limited,
UK
Dr. Bernd Eisele,
CEO,
VPM Inc.,
Germany
Dr. Jose M. Galarza,
CEO,
TechnoVax, Inc.,
USA
Dr. Jeanne Novak,
President and Chief Executive Officer,
CBR International Corporation,
USA
Dr. Tomas Jelinek,
Medical Director,
Berlin Centre for Travel & Tropical Medicine,
Germany

BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2015-2016 BIT Congress Inc.